Differences in the expression and effects of interleukin-1 and -2 on androgen-sensitive and -insensitive human prostate cancer cell lines

Cancer Letters

Volumn 149, Issue 1-2, 2000, Pages 37-42

  Abdul, Mansoor ^a   Hoosein, Naseema ^a,b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Androgen; Interleukin 1; Interleukin 2; Proliferation; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 2;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; CELL DIVISION; HUMANS; INTERLEUKIN-1; INTERLEUKIN-2; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033964131     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00341-9     Document Type: Article

References (20)

1. Abdul M., Hsieh J.T., Logothetis C.J., Hoosein N.M. Secretion of prostate-specific antigen (PSA)-suppressing activity by two human prostate carcinoma cell lines. Urologic. Oncol. 1:1995;38-41.
2. Dveksler G.S., Basile A.A., Dieffenbach C.W. Analysis of gene expression: use of oligonucleotide primers for glyceraldehyde-3-phosphate dehydrogenase. PCR Methods Applications. 1:1992;283-285.
3. Navone N.M., Olive M., Ozen M., Davis R., Troncoso P., Tu S.-M., Johnston D., Pollack A., Pathak A.C., von Eshenbach A.C., Logothetis C.J. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res. 3:1997;2493-2500.
4. Diaz M., Abdul M., Hoosein N.M. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate Suppl. 8:1998;32-36.
5. Lu C., Kerbel R.S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol. 120:1993;1281-1288.
6. Hoosein N.M., McKnight M.K., Levine A.E., Mulder K.M., Childress K.E., Brattain D.E., Brattain M.G. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. Exp. Cell Res. 181:1989;442-453.
7. Anasagasti M.J., Olaso E., Calvo F., Mendoza L., Martin J.J., Bidaurrazaga J., Vidal-Vanaclocha F. Interleukin 1-dependent and -independent mouse melanoma metastases. J. Natl. Can. Inst. 89:1997;645-651.
8. Li B.Y., Mohanraj D., Olson M.C., Moradi M., Twiggs L., Carson L.F., Ramakrishnan S. Human ovarian epithelial cancer cells cultures in vitro express both interleukin 1 alpha and beta genes. Cancer Res. 52:1992;2248-2252.
9. Paciotti G.F., Tamarkin L. Interleukin-1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro. Mol. Endocrinol. 2:1998;459-464.
10. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J. Cell. Biochem. 53:1993;288-295.
11. Klein R.D., Borchers A.H., Sundareshan P., Bougelet C., Berkman M.R., Nagle R.B., Bowden G.T. Interleukin-1beta secreted from monocytic cells induces the expression of matrilysin in the prostatic cell line LNCaP. J. Biol. Chem. 272:1997;14188-14192.
12. Jones T.H., Justice S.K., Timperley W.R., Royds J.A. Effect of interleukin-1 and dexamethasone on interleukin-6 production and growth in human meningiomas. J. Pathol. 183:1997;460-468.
13. Beasley D. Phorbol ester and interleukin-1 induce interleukin-6 gene expression in vascular smooth muscle cells via independent pathways. J. Cardiovasc. Pharmacol. 29:1997;323-330.
14. Twillie D.A., Eisenburger M.A., Carducci M.A., Hsieh W-S., Kim W.Y., Simons J.W. Interleukin 6: a candidate mediator of human prostate cancer morbidity. Urology. 45:1995;542-549.
15. Hoosein N.M., Abdul M., McCabe R., Gero E., Deftos L., Banks M., Hodges S., Finn L., Logothetis C.J. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol. Oncol. 1:1995;246-251.
16. Hoosein N.M., Finn L., Hodges S., Diaz M., Abdul M. Soluble markers of PCa progression. Can. Res. Ther. Control. 7:1998;233-237.
17. Qiu Y., Robinson D., Pretlow T.G., Kung H.J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA. 95:1998;3644-3649.
18. Culig Z., Hobisch A., Herold I., Hittmair A., Thurnher M., Eder I.E., Cronauer M.V., Rieser C., Ramoner R., Bartsch G., Klocker H., Konwalinka G. Interleukin-1 beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. Br. J. Cancer. 78:1998;1004-1011.
19. Paciotti G.F., Tamarkin L. Interleukin-2 differentially affects the proliferation hormone-dependent and hormone-independent human breast cancer cell lines in-vitro and in-vivo. Anticancer Res. 8:1998;1233-1240.
20. Boyano D.M., Garcia de Galdeano A., Smith-Zubiaga I., Canavate M.L. IL-2 treatment of B16F10 melanoma cells stimulates metastatic colonization in the liver. Anticancer Res. 17:1997;1135-1142.